Kenneth Abreo
Nephrology · Shreveport, LANPI 1750303145
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,400 of the $42,482 with a category attached, or 71.6%. Calliditas Therapeutics US Inc. accounts for 86.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $29,851 and has fallen 95.3% since, to $1,408 in 2025. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $150.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$37K
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$931
- Mallinckrodt Hospital Products Inc.$595
- Amgen$490
- Fresenius USA Marketing, Inc.$364
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,9007%
- Speaking & faculty fees$30,40072%
- Travel & lodging$2,5346%
- Food & beverage$6,26815%
- Education$3801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 50 | $36,761 |
| AstraZeneca(2 entities) | 68 | $1,264 |
| Otsuka America Pharmaceutical, Inc. | 37 | $931 |
| Mallinckrodt Hospital Products Inc. | 23 | $595 |
| Amgen(2 entities) | 15 | $490 |
| Fresenius USA Marketing, Inc. | 20 | $364 |
| Travere Therapeutics, Inc. | 10 | $361 |
| Aurinia Pharma U.S., Inc. | 5 | $219 |
| Nxstage Medical, Inc. | 4 | $205 |
| GSK | 12 | $188 |
| Novartis | 6 | $164 |
| Daiichi Sankyo Inc. | 8 | $161 |
| Vifor Pharma, Inc. | 7 | $154 |
| Mallinckrodt Enterprises LLC | 2 | $125 |
| W. L. Gore & Associates, Inc. | 1 | $124 |
| Bayer | 5 | $116 |
| AV Medical Technologies Ltd. | 1 | $72 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| Covidien LP | 1 | $39 |
| Akebia Therapeutics Inc | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Sanofi | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$36,265
- JYNARQUE$191
- NXSTAGE SYSTEM ONE$150
- NXSTAGE PUREFLOW SOLUTION$150
- TERLIVAZ$125
- KRYSTEXXA$125
- ACUSEAL Vascular Graft$124
How this compares
$42,482 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 17 | $53,347 |
| FarxigaDapagliflozin Propanediol | 39 | $27,295 |
| JardianceEmpagliflozin | 25 | $22,330 |
| FosrenolLanthanum Carbonate | 11 | $11,954 |
| Sevelamer Carbonate | 88 | $11,388 |
| Nifedipine ErNifedipine | 46 | $632 |
| Chlorthalidone | 14 | $301 |
| Losartan Potassium | 31 | $214 |
| Atorvastatin Calcium | 22 | $92 |
| Carvedilol | 19 | $77 |
| Gabapentin | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $364 | $53,34717 claims |
| AstraZenecaFarxiga | $1,264 | $27,29539 claims |
| Boehringer IngelheimJardiance | $19 | $22,33025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Shreveport
- Sreedhara AllaShreveport$722K
- Raja ZabanehShreveport$57K
- Neville DossabhoyShreveport$19K
- Marwan KaskasShreveport$18K
- Adrian SequeiraShreveport$18K
- Zulqarnain AbroShreveport$9K
- Cheng ChuShreveport$8K
- Arnold BarzShreveport$7K
- Srinivasa IskapalliShreveport$5K
- Adrian AbreoShreveport$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.